Literature DB >> 1733389

Predictors of mortality among HIV-infected women in Kigali, Rwanda.

C P Lindan1, S Allen, A Serufilira, A R Lifson, P Van de Perre, A Chen-Rundle, J Batungwanayo, F Nsengumuremyi, J Bogaerts, S Hulley.   

Abstract

OBJECTIVE: To better characterize the natural history of disease due to human immunodeficiency virus (HIV) infection in African women.
DESIGN: Prospective cohort study over a 2-year follow-up period. PARTICIPANTS: A total of 460 HIV-seropositive women and a comparison cohort of HIV-seronegative women recruited from prenatal and pediatric clinics in Kigali, Rwanda in 1988. MEASUREMENTS: Clinical signs and symptoms of HIV disease, AIDS, and mortality. MAIN
RESULTS: Follow-up data at 2 years were available for 93% of women who were still alive. At enrollment, many seropositive women reported symptoms listed in the World Health Organization (WHO) clinical case definition of AIDS, but these were nonspecific and often improved over time. The 2-year mortality among HIV-infected women by Kaplan-Meier survival analysis was 7% (95% CI, 5% to 10%) overall, and 21% (CI, 8% to 34%) for the 40 women who fulfilled the WHO case definition of AIDS at entry. In comparison, the 2-year mortality in women not infected with HIV was only 0.3% (CI, 0% to 7%). Independent baseline predictors of mortality in seropositive women by Cox proportional hazards modeling were, in order of descending risk factor prevalence: a body mass index of 21 kg/m2 or less (relative hazard, 2.3; CI, 1.1 to 4.8), low income (relative hazard, 2.3; CI, 1.1 to 4.5), an erythrocyte sedimentation rate exceeding 60 mm/h (relative hazard, 4.9; CI, 2.2 to 10.9), chronic diarrhea (relative hazard, 2.6; CI, 1.1 to 5.7), a history of herpes zoster (relative hazard 5.3; CI, 2.5 to 11.4), and oral candida (relative hazard, 7.3; CI, 1.6 to 33.3). Human immunodeficiency virus disease was the cause of death in 38 of the 39 HIV-positive women who died, but only 25 met the WHO definition of AIDS before death.
CONCLUSIONS: Human immunodeficiency virus disease now accounts for 90% of all deaths among child-bearing urban Rwandan women. Many symptomatic seropositive patients may show some clinical improvement and should not be denied routine medical care. Easily diagnosed signs and symptoms and inexpensive laboratory tests can be used in Africa to identify those patients with a particularly good or bad prognosis.

Entities:  

Keywords:  Acquired Immunodeficiency Syndrome; Africa; Africa South Of The Sahara; Biology; Case Control Studies; Cohort Analysis; Demographic Analysis; Demographic Factors; Developing Countries; Diseases; Eastern Africa; Economic Factors; Erythrocyte Sedimentation Rate; Examinations And Diagnoses; Follow-up Studies; French Speaking Africa; Hematological Effects; Hemic System; Hiv Infections; Laboratory Examinations And Diagnoses; Laboratory Procedures; Life Table Method; Mortality; Mortality Determinants--women; Physiology; Population; Population Characteristics; Population Dynamics; Poverty; Research Methodology; Rwanda; Signs And Symptoms; Socioeconomic Factors; Studies; Urban Population--women; Viral Diseases

Mesh:

Year:  1992        PMID: 1733389     DOI: 10.7326/0003-4819-116-4-320

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  30 in total

1.  Increased risk of mortality and loss to follow-up among HIV-positive patients with oropharyngeal candidiasis and malnutrition before antiretroviral therapy initiation: a retrospective analysis from a large urban cohort in Johannesburg, South Africa.

Authors:  Denise Evans; Mhairi Maskew; Ian Sanne
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2012-03

2.  Body mass index and risk of tuberculosis and death.

Authors:  Colleen F Hanrahan; Jonathan E Golub; Lerato Mohapi; Nkeko Tshabangu; Tebogo Modisenyane; Richard E Chaisson; Glenda E Gray; James A McIntyre; Neil A Martinson
Journal:  AIDS       Date:  2010-06-19       Impact factor: 4.177

3.  Correlation of partial env gene sequences with disease progression parameters in HIV-positive pregnant women from India.

Authors:  Supriya Singh; Shashi Khare; Sudha Prasad; R L Ichhpujani; S S Negi; Sachin Kumar; D S Rawat; L S Chauhan; Arvind Rai
Journal:  Med Microbiol Immunol       Date:  2012-01-25       Impact factor: 3.402

4.  AIDS survival and progression in black Africans living in south London, 1986-1994.

Authors:  N Low; K Paine; R Clark; M Mahalingam; A L Pozniak
Journal:  Genitourin Med       Date:  1996-02

5.  HIV morbidity and mortality in Jamaica: analysis of national surveillance data, 1993--2005.

Authors:  Elena Losina; Peter Figueroa; Jacqueline Duncan; Nomita Divi; Lindsey L Wolf; Lisa R Hirschhorn; Minnette Robertson; Kevin Harvey; Sheldon Whorms; Kenneth A Freedberg; Yitades Gebre
Journal:  Int J Infect Dis       Date:  2007-08-13       Impact factor: 3.623

6.  Progression to symptomatic disease in people infected with HIV-1 in rural Uganda: prospective cohort study.

Authors:  Dilys Morgan; Cedric Mahe; Billy Mayanja; James A G Whitworth
Journal:  BMJ       Date:  2002-01-26

7.  Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels.

Authors:  S Bhasin; T W Storer; M Javanbakht; N Berman; K E Yarasheski; J Phillips; M Dike; I Sinha-Hikim; R Shen; R D Hays; G Beall
Journal:  JAMA       Date:  2000-02-09       Impact factor: 56.272

8.  HIV-1 incidence and HIV-1 associated mortality in a cohort of urban factory workers in Tanzania.

Authors:  M W Borgdorff; L R Barongo; A H Klokke; J N Newell; K P Senkoro; J P Velema; R M Gabone
Journal:  Genitourin Med       Date:  1995-08

9.  Pregnancy and contraception use among urban Rwandan women after HIV testing and counseling.

Authors:  S Allen; A Serufilira; V Gruber; S Kegeles; P Van de Perre; M Carael; T J Coates
Journal:  Am J Public Health       Date:  1993-05       Impact factor: 9.308

10.  Comparison of media for optimal recovery of Candida albicans and Candida glabrata from blood culture.

Authors:  J E Moore; R McMullan
Journal:  Ir J Med Sci       Date:  2003 Apr-Jun       Impact factor: 1.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.